Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sunitinib in relapsed or cisplatin-refractory germ cell cancer
2006-004667-61Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in Germ Cell Testicular Cancer, sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Objective tumor response rate. Started Jan 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
Germ Cell Testicular Cancer
Beyond the preview
Go deeper on 2006-004667-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004667-61.